Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

Gregory P. Bisson; Lynne Jones; Johnstone Kumwenda; Vidya Mave; Sandy Pillay; Amita Gupta; Valdiléa G. Veloso; Andrew Zolopa; Nagalingeswaran Kumarasamy; Jing Bao; Kogieleum Naidoo; Xin Sun; Jorge Alave; Mina C. Hosseinipour; David Lagat; Evelyn Hogg; Lerato Mohapi; Cynthia Riviere; Javier R. Lama; Agnes Moses

doi:10.17615/sfnd-rt19

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

Author(s)

Gregory P. Bisson

Lynne Jones

Johnstone Kumwenda

Vidya Mave

Sandy Pillay

Amita Gupta

Valdiléa G. Veloso

Andrew Zolopa

Nagalingeswaran Kumarasamy

Jing Bao

Kogieleum Naidoo

Xin Sun

Mina C. Hosseinipour

David Lagat

Evelyn Hogg

Lerato Mohapi

Cynthia Riviere

Javier R. Lama

Agnes Moses

Peter Mugyenyi

Fredrick K Kirui

Sharlaa Badal‐Faesen

James Hakim

Sachiko Miyahara

Germán Henostroza

Mulinda Nyirenda

Paul Leger

Date Issued

22 de abril de 2020

Type

Article

DOI

10.17615/sfnd-rt19

Abstract

Mortality within the first 6 months after initiating antiretroviral therapy (ART) is common in resource-limited settings and is often due to tuberculosis (TB) among patients with advanced HIV disease. Isoniazid preventive therapy (IPT) is recommended in HIV-infected adults, but sub-clinical TB can be difficult to diagnose. We hypothesized that empiric TB treatment would reduce early mortality compared to IPT in high-burden settings.